Development and Assessment of a Rapid Diagnostic Protocol for Antibiotic-Resistant Bacteria

Thesis Abstract

The escalating global prevalence of antibiotic-resistant bacteria represents a critical challenge to effective clinical management and public health systems, underscoring the urgent need for rapid, reliable diagnostic methods to identify resistant strains promptly. Traditional microbiological techniques, while accurate, are often labor-intensive and time-consuming, delaying appropriate antimicrobial therapy and contributing to the proliferation of resistant pathogens. This study aims to develop and rigorously assess a novel rapid diagnostic protocol that combines molecular and phenotypic techniques to detect antibiotic resistance in bacterial pathogens within a two-hour timeframe. The specific objectives are to design an integrated diagnostic workflow utilizing real-time PCR and microfluidic biosensing platforms, evaluate its sensitivity, specificity, and turnaround time compared to standard culture-based methods, and validate the protocol across clinically relevant bacterial species, including Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. Employing a mixed-methods research design, the study encompasses both laboratory-based experimental development and field validation. The population comprises clinical bacterial isolates collected from hospital diagnostic laboratories in a metropolitan healthcare setting, with a total sample size of 200 isolates (100 resistant and 100 susceptible), selected via stratified random sampling to ensure representative diversity across pathogenic species and resistance profiles. Data collection instruments include custom-designed multiplex real-time PCR assays targeting key resistance genes (e.g., bla_KPC, mecA, vanA), microfluidic biosensors for phenotypic resistance detection, and standard culture-based sensitivity testing as the reference gold standard. Instrument validity is established through calibration with characterized control strains, and reliability is assessed via repeatability tests involving intra- and inter-assay variability measures. Analytical techniques involve quantitative analysis of diagnostic accuracy metrics—sensitivity, specificity, positive predictive value, and negative predictive value—computed using standard 2x2 contingency tables. Comparative analysis of turnaround times is performed using paired t-tests. Receiver operating characteristic (ROC) curves evaluate the diagnostic performance, while regression analysis explores correlations between gene detection levels and phenotypic resistance. The conceptual framework integrates the bioinformatics-based molecular detection model with the microfluidic biosensing principles grounded in the Theory of Technological Innovation Adoption, providing a comprehensive understanding of the protocol’s operational efficacy. Ethical considerations include obtaining institutional review board approval, guardian consent for clinical isolate use, and adherence to biosafety standards. Expected findings will demonstrate that the integrated rapid diagnostic protocol achieves a sensitivity and specificity exceeding 90% within a 2-hour window, significantly outperforming the traditional methods, which typically require 24-48 hours. The microfluidic platform is anticipated to offer high reproducibility and portability, enabling deployment in point-of-care settings, while molecular assays provide precise identification of resistance genes. The study will contribute to the existing body of knowledge by providing a validated, scalable diagnostic framework that accelerates antibiotic resistance detection, ultimately facilitating timely and targeted antimicrobial therapy. The main conclusion emphasizes that the developed protocol offers a feasible, accurate, and rapid diagnostic alternative suitable for clinical implementation, thereby potentially reducing inappropriate antibiotic use and curbing the spread of resistant bacteria. Recommendations include integrating this protocol into routine diagnostic workflows, expanding validation to broader bacterial species, and exploring automation for large-scale deployment. Future research should investigate the protocol’s adaptability to emerging resistance mechanisms and its economic feasibility in various healthcare contexts, aiming to bridge laboratory innovation with widespread clinical application.